Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

Cancer Immunology, Immunotherapy

Volumn 60, Issue 4, 2011, Pages 467-477

  Di Giacomo, Anna Maria ^a   Danielli, Riccardo ^a   Calabrò, Luana ^a   Bertocci, Erica ^a   Nannicini, Chiara ^a   Giannarelli, Diana ^b   Balestrazzi, Angelo ^a   Vigni, Francesco ^a   Riversi, Valentina ^a   Miracco, Clelia ^a   Biagioli, Maurizio ^a   Altomonte, Maresa ^a   Maio, Michele ^a,c  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Advanced melanoma; Compassionate use; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Ipilimumab; Monoclonal antibody

Indexed keywords

AMYLASE; IPILIMUMAB; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE MELANOMA; FATALITY; FEMALE; FOLLOW UP; HUMAN; ITALY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; MELANOMA; MONOTHERAPY; MUCOSAL MELANOMA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SURVIVAL RATE; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SALVAGE THERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 79953784382     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0958-2     Document Type: Article

References (37)

1. Chandy BK (2006) WHO - Facts Sheet: health consequences of excessive solar UV radiation. Kuwait Med J 38:254-258
2. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19:19-25
3. Korn EL, Liu P-Y, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin OncoI 26:527-534 (Pubitemid 351264344)
4. Seetharamu N, Ott PA, Pavlick AC (2009) Novel therapeutics for melanoma. Exp Rev Anticancer Ther 9:839-849
5. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488-496
6. Bedikian AY, Millward M, Pehamberger H et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745 (Pubitemid 46630937)
7. Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116 (Pubitemid 29318842)
8. Crowley NJ, Seigler HF (1993) Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 9:273-278 (Pubitemid 23154467)
9. Langer LF, Clay TM, Morse MA (2007) Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7:1245-1256 (Pubitemid 47305249)
10. Morse MA (2005) Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther 7:588-597
11. Fong L, Small EJ (2008) Anticytotoxic T-Lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283
12. Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005-1016 (Pubitemid 41660676)
13. Weber JS (2007) Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864-872
14. Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297-1306
15. Maio M, Lebbé C, Neyns B et al Three-year survival rates for patients with advanced melanoma who received ipilimumab at 10 mg/kg in phase II trials. Presented at: Perspectives in Melanoma XIV; September 17-18, 2010; Amsterdam, The Netherlands. Poster P-0020
16. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
17. Wolchok JD, dePril V, Linette G et al (2009) Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors. J Clin Oncol 27:[Suppl.; abstr 9036]
18. Hamid O, Urba WJ, Yellin M et al (2007) Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol 25:[Suppl.; abstr 8525]
19. Hodi FS, Hoos A, O'Day S et al (2008) Novel efficacy criteria for anti-tumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 26:[Suppl.; abstr 3008]
20. Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053
21. Beck KE, Blansfield JA, Tran KQ et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289 (Pubitemid 46630658)
22. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci 100:8372-8377 (Pubitemid 36842552)
23. Ledezma B (2009) Ipilimumab for advanced melanoma: a nursing perspective. Oncol Nurs Forum 36:97-104
24. Lin R, Yellin MJ, Lowy I et al (2008) An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 26:[Suppl.; abstr 9063]
25. Lutzky J, Wolchok J, Hamid O et al (2009) Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27:[Suppl.; abstr 9034]
26. Harmankaya K, Minor D, Linette G et al Ipilimumab re-induction after progression in patients with advanced melanoma enrolled in phase II clinical trials. Presented at: Joint ECCO 15-34th ESMO Multidisciplinary Congress; September 20-24, 2009; Berlin, Germany
27. O'Day SJ, Maio M, Chiarion-Sileni V et al (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21:1712-1717
28. Aamdal S, Wolchok JD, Weber J et al (2009) Changes in peripheral blood absolute lymphocyte count (ALC) may guide patient selection for continued treatment with ipilimumab. Eur J Cancer 7(Suppl. N2):579
29. Schmidt H, Hamid O, Nissan A et al (2009) Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma. Eur J Cancer 7(Suppl. N2):577
30. Wolchok JD, Hoos A, O'Day SJ et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res 15:7412-7420
31. O'Day SJ, Weber J, Lebbe C et al (2009) Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27:(Suppl.; abstr 9033)
32. Hersh J, Weber J, Powderly J et al (2009) Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine. J Clin Oncol 27:(Suppl.; abstr 9038)
33. O'Day SJ, Weber JS, Hamid O et al Completed phase II clinical trials: experience with 10 mg/kg ipilimumab for the treatment of advanced melanoma. Presented at: World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers; November 19-21, 2009; Berlin, Germany. Poster 41
34. Ku GY, Yuan J, Page DB et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775
35. Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37:499-507
36. Kaehler KC, Piel S, Livingstone E et al (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37:485-498
37. National Monitoring Center for Clinical Trials (Italy). A singlearm phase II study of a combination of ipilimumab and fotemustine in patients with unresectable stage III or IV melanoma. EudraCT Number 2010-019356-50. http://oss-sper-clin.agenziafarmaco.it/cgi-bin/ricerca-sperim-keyword-pp